NovoCure Ltd.
- NVCR · Nasdaq
- Surgical & Medical Instruments & Apparatus
- St. Helier, Jersey
- 1,605 employees
- CIK 0001645113
Updated from SEC filings through
Top things to know
Executives
- Frank Leonard CEO, Novocure 8-K, 2026-10-29
- Frank X. Leonard Chief Executive Officer 4, 2026-07-01
- Ashley Cordova Former Chief Executive Officer 4, 2026-03-05
- Christoph Brackmann Chief Financial Officer 4, 2026-03-05
- Michal Nath Puri Chief Human Resources Officer 4, 2026-07-01
- Mukund Paravasthu Chief Operating Officer 4, 2026-03-05
What leadership is saying
“Novocure’s strong third quarter performance was driven by continued growth in our Optune Gio business and our growing portfolio of products launching in new markets, resulting in a record number of active patients on our therapies”
Earnings press release (8-K Ex. 99.1), filed October 29, 2026
NovoCure Ltd is a U.S. public company in surgical & medical instruments & apparatus (SIC 3841), headquartered in St. Helier, Jersey. It trades as NVCR on Nasdaq. Revenue was $655M in the fiscal year ending December 31, 2025, +8.3% from the year before. It reported about 1,605 employees. Frank Leonard is CEO, Novocure.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $655M 10-Q, 2026-10-29 | $605M 10-K, 2026-02-26 | $509M 10-K, 2026-02-26 | $538M 10-K, 2025-02-27 | $535M 10-K, 2024-02-22 |
| Operating income | -$154M 10-Q, 2026-10-29 | -$170M 10-K, 2026-02-26 | -$233M 10-K, 2026-02-26 | -$89.5M 10-K, 2025-02-27 | -$44.3M 10-K, 2024-02-22 |
| SG&A | $418M 10-Q, 2026-10-29 | $429M 10-K, 2026-02-26 | $391M 10-K, 2026-02-26 | $306M 10-K, 2025-02-27 | $263M 10-K, 2024-02-22 |
| Net income | -$136M 10-Q, 2026-10-29 | -$169M 10-K, 2026-02-26 | -$207M 10-K, 2026-02-26 | -$92.5M 10-K, 2025-02-27 | -$58.4M 10-K, 2024-02-22 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Frank Leonard | CEO, Novocure | 8-K, 2026-10-29 |
| Frank X. Leonard | Chief Executive Officer | 4, 2026-07-01 |
| Ashley Cordova | Former Chief Executive Officer | 4, 2026-03-05 |
| Christoph Brackmann Chief Financial Officer at Novocure | Chief Financial Officer | 4, 2026-03-05 |
| Michal Nath Puri | Chief Human Resources Officer | 4, 2026-07-01 |
| Nicholas Leupin | Named in proxy bio: Former Chief Medical Officer | DEF 14A, 2026-04-20 |
| Mukund Paravasthu SVP, Product Development at Novocure | Chief Operating Officer | 4, 2026-03-05 |
| Nicolas Leupin | Former Chief Medical Officer | 4, 2026-03-05 |
| Michael Puri CHRO Novocure | Chief Human Resources Officer | 10-K, 2026-02-26 |
| Arye Barak Ben | General Counsel | 4, 2026-07-01 |
| Uri Weinberg Chief Innovation Officer & Chief Medical Officer at Novocure | Chf Medical and Innovation Ofr | 4, 2026-03-05 |
| William F. Doyle | Executive Chairman | 4, 2026-03-05 |
| Barak Ben-Arye | General Counsel | 10-K, 2026-02-26 |
| Allyson Ocean | director | 8-K, 2026-06-05 |
| Asaf Danziger | director | 8-K, 2026-06-05 |
| David Hung | director | 8-K, 2026-06-05 |
What NovoCure Ltd does
We are a global oncology company with a proprietary platform technology called Tumor Treating Fields ("TTFields"), which are electric fields that exert physical forces to kill cancer cells. Our therapy is delivered through a medical device.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 116.9 million (as of October 23, 2026) | 10-Q, October 29, 2026 |
|---|---|---|
| Public float | $995M (as of June 30, 2025) | 10-K, February 26, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, October 29, 2026 |
| Latest proxy statement | Meeting June 3, 2026 (filed April 20, 2026) | DEF 14A, April 20, 2026 |
| Auditor | Kost Forer Gabbay & Kasierer (Israel) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 2, 2026 | Michal Nath Puri Chief Human Resources Officer | Sale | 660 | $9K | Form 4, November 4, 2026 |
| June 4, 2026 | Frank X. Leonard Chief Executive Officer | Sale | 34,273 | $615K | Form 4, June 5, 2026 |
| June 2, 2026 | Kristin Stafford Director | Sale | 2,945 | $46K | Form 4, June 3, 2026 |
| June 2, 2026 | Allyson J. Ocean Director | Sale | 2,945 | $46K | Form 4, June 3, 2026 |
| June 2, 2026 | Timothy J. Scannell Director | Sale | 2,945 | $46K | Form 4, June 3, 2026 |
| June 2, 2026 | W. Anthony Vernon Director | Sale | 2,945 | $46K | Form 4, June 3, 2026 |
| June 2, 2026 | David Hung Director | Sale | 2,945 | $46K | Form 4, June 3, 2026 |
| June 2, 2026 | Gabriel Leung Director | Sale | 2,945 | $46K | Form 4, June 3, 2026 |
Recent 8-K events
- 8-K filed 2026-10-29
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-10-01
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-09-09
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-09-01
- Item 8.01 Other events
- 8-K filed 2026-07-23
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-06-30
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-06-18
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-06-05
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-04-30
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-04-09
- Item 5.02 Departure or appointment of directors or officers; compensation
Frequently asked questions about NovoCure Ltd
- What does NovoCure Ltd do?
- In its own words, from Item 1 of its 10-K: "We are a global oncology company with a proprietary platform technology called Tumor Treating Fields ("TTFields"), which are electric fields that exert physical forces to kill cancer cells. Our therapy is delivered through a medical device."
- What is NovoCure Ltd's revenue?
- $655M for the fiscal year ending December 31, 2025, from its 10-Q filed October 29, 2026.
- Is NovoCure Ltd profitable?
- NovoCure Ltd reported net income of -$136M for the fiscal year ending December 31, 2025.
- How many employees does NovoCure Ltd have?
- About 1,605 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of NovoCure Ltd?
- Frank Leonard, CEO, Novocure, as named in a 8-K filed October 29, 2026.
- Who is the CFO of NovoCure Ltd?
- Christoph Brackmann, Chief Financial Officer, as named in a 4 filed March 5, 2026.
- Where is NovoCure Ltd headquartered?
- St. Helier, Jersey.
- What is NovoCure Ltd's stock ticker?
- NVCR on Nasdaq.
- What industry is NovoCure Ltd in?
- Surgical & Medical Instruments & Apparatus, SIC code 3841.
- What is NovoCure Ltd's website?
- novocure.com.
- When does NovoCure Ltd report earnings next?
- December 18, 2026. Source: estimate_8k_pattern.
- Is NovoCure Ltd a public company?
- Yes. NovoCure Ltd files with the SEC under CIK 0001645113 and trades as NVCR.
- Who audits NovoCure Ltd?
- Kost Forer Gabbay & Kasierer, Israel, as named in its latest annual report (10-K).
- How many shares of NovoCure Ltd are outstanding?
- 116.9 million shares as of October 23, 2026, from its 10-Q filed October 29, 2026.
- What is NovoCure Ltd's public float?
- $995M as of June 30, 2025, as reported on the cover of its 10-K filed February 26, 2026.
- How many business segments does NovoCure Ltd report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed October 29, 2026.
- When is NovoCure Ltd's annual shareholder meeting?
- June 3, 2026, per its proxy statement (DEF 14A) filed April 20, 2026.
- Have NovoCure Ltd insiders traded stock recently?
- Since July 29, 2025, officers and directors reported 21 open-market sales worth about $3.3M and 2 purchases worth about $1.2M on Forms 4 and 5. The most recent: Michal Nath Puri (Chief Human Resources Officer) sold 660 shares on November 2, 2026.